Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers

L. Forsberg, T. Spelman, P. Klyve, A. Manouchehrinia, R. Ramanujam, E. Mouresan, J. Drahota, D. Horakova, H. Joensen, L. Pontieri, M. Magyari, D. Ellenberger, A. Stahmann, J. Rodgers, J. Witts, R. Middleton, R. Nicholas, V. Bezlyak, N. Adlard, T....

. 2023 ; 9 (1) : 20552173231153557. [pub] 20230216

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23002905

BACKGROUND: To assign a course of secondary progressive multiple sclerosis (MS) (SPMS) may be difficult and the proportion of persons with SPMS varies between reports. An objective method for disease course classification may give a better estimation of the relative proportions of relapsing-remitting MS (RRMS) and SPMS and may identify situations where SPMS is under reported. MATERIALS AND METHODS: Data were obtained for 61,900 MS patients from MS registries in the Czech Republic, Denmark, Germany, Sweden, and the United Kingdom (UK), including date of birth, sex, SP conversion year, visits with an Expanded Disability Status Scale (EDSS) score, MS onset and diagnosis date, relapses, and disease-modifying treatment (DMT) use. We included RRMS or SPMS patients with at least one visit between January 2017 and December 2019 if ≥ 18 years of age. We applied three objective methods: A set of SPMS clinical trial inclusion criteria ("EXPAND criteria") modified for a real-world evidence setting, a modified version of the MSBase algorithm, and a decision tree-based algorithm recently published. RESULTS: The clinically assigned proportion of SPMS varied from 8.7% (Czechia) to 34.3% (UK). Objective classifiers estimated the proportion of SPMS from 15.1% (Germany by the EXPAND criteria) to 58.0% (UK by the decision tree method). Due to different requirements of number of EDSS scores, classifiers varied in the proportion they were able to classify; from 18% (UK by the MSBase algorithm) to 100% (the decision tree algorithm for all registries). Objectively classified SPMS patients were older, converted to SPMS later, had higher EDSS at index date and higher EDSS at conversion. More objectively classified SPMS were on DMTs compared to the clinically assigned. CONCLUSION: SPMS appears to be systematically underdiagnosed in MS registries. Reclassified patients were more commonly on DMTs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23002905
003      
CZ-PrNML
005      
20230421100050.0
007      
ta
008      
230413s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/20552173231153557 $2 doi
035    __
$a (PubMed)36816812
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Forsberg, Lars $u Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000235361813
245    10
$a Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers / $c L. Forsberg, T. Spelman, P. Klyve, A. Manouchehrinia, R. Ramanujam, E. Mouresan, J. Drahota, D. Horakova, H. Joensen, L. Pontieri, M. Magyari, D. Ellenberger, A. Stahmann, J. Rodgers, J. Witts, R. Middleton, R. Nicholas, V. Bezlyak, N. Adlard, T. Hach, C. Lines, S. Vukusic, M. Soilu-Hänninen, A. van der Walt, H. Butzkueven, P. Iaffaldano, M. Trojano, A. Glaser, J. Hillert, SPMS Research Collaboration Network
520    9_
$a BACKGROUND: To assign a course of secondary progressive multiple sclerosis (MS) (SPMS) may be difficult and the proportion of persons with SPMS varies between reports. An objective method for disease course classification may give a better estimation of the relative proportions of relapsing-remitting MS (RRMS) and SPMS and may identify situations where SPMS is under reported. MATERIALS AND METHODS: Data were obtained for 61,900 MS patients from MS registries in the Czech Republic, Denmark, Germany, Sweden, and the United Kingdom (UK), including date of birth, sex, SP conversion year, visits with an Expanded Disability Status Scale (EDSS) score, MS onset and diagnosis date, relapses, and disease-modifying treatment (DMT) use. We included RRMS or SPMS patients with at least one visit between January 2017 and December 2019 if ≥ 18 years of age. We applied three objective methods: A set of SPMS clinical trial inclusion criteria ("EXPAND criteria") modified for a real-world evidence setting, a modified version of the MSBase algorithm, and a decision tree-based algorithm recently published. RESULTS: The clinically assigned proportion of SPMS varied from 8.7% (Czechia) to 34.3% (UK). Objective classifiers estimated the proportion of SPMS from 15.1% (Germany by the EXPAND criteria) to 58.0% (UK by the decision tree method). Due to different requirements of number of EDSS scores, classifiers varied in the proportion they were able to classify; from 18% (UK by the MSBase algorithm) to 100% (the decision tree algorithm for all registries). Objectively classified SPMS patients were older, converted to SPMS later, had higher EDSS at index date and higher EDSS at conversion. More objectively classified SPMS were on DMTs compared to the clinically assigned. CONCLUSION: SPMS appears to be systematically underdiagnosed in MS registries. Reclassified patients were more commonly on DMTs.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Spelman, Tim $u Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Klyve, Pernilla $u Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Manouchehrinia, Ali $u Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden $u Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000348575762
700    1_
$a Ramanujam, Ryan $u Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden $u Department of Mathematics, Royal Institute of Technology, Stockholm, Sweden $1 https://orcid.org/0000000173601497
700    1_
$a Mouresan, Elena $u Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Drahota, Jiri $u Czech National Multiple Sclerosis ReMuS, IMPULS Endowment Fund, Prague, Czech Republic $u First Faculty of Medicine and General University Hospital, Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, Prague, Czech Republic $1 https://orcid.org/0000000334162094
700    1_
$a Horakova, Dana $u First Faculty of Medicine and General University Hospital, Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, Prague, Czech Republic $1 https://orcid.org/0000000319150036
700    1_
$a Joensen, Hanna $u The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Copenhagen, Denmark
700    1_
$a Pontieri, Luigi $u The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Copenhagen, Denmark $1 https://orcid.org/0000000215063827
700    1_
$a Magyari, Melinda $u The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Copenhagen, Denmark $u Danish Multiple Sclerosis Center, Copenhagen University Hospital, Copenhagen, Denmark
700    1_
$a Ellenberger, David $u MS Forschungs- und Projektentwicklungs-gGmbH, Hannover, Germany $1 https://orcid.org/0000000222745025
700    1_
$a Stahmann, Alexander $u MS Forschungs- und Projektentwicklungs-gGmbH, Hannover, Germany $1 https://orcid.org/000000015308105X
700    1_
$a Rodgers, Jeff $u Swansea University Medical School, Swansea, UK $1 https://orcid.org/0000000307573664
700    1_
$a Witts, James $u Swansea University Medical School, Swansea, UK
700    1_
$a Middleton, Rod $u Swansea University Medical School, Swansea, UK
700    1_
$a Nicholas, Richard $u Swansea University Medical School, Swansea, UK $u Department of Cellular and Molecular Neuroscience, Imperial College London, London, UK $1 https://orcid.org/0000000304141225
700    1_
$a Bezlyak, Vladimir $u Novartis Pharma AG, Basel, Switzerland
700    1_
$a Adlard, Nicholas $u Novartis Pharma AG, Basel, Switzerland
700    1_
$a Hach, Thomas $u Novartis Pharma AG, Basel, Switzerland
700    1_
$a Lines, Carol $u Novartis Pharma AG, Basel, Switzerland
700    1_
$a Vukusic, Sandra $u Hôpital Neurologique, Service de Neurologie A, the European Database for Multiple Sclerosis (EDMUS), Coordinating Center and INSERM U 433, Lyon, France $1 https://orcid.org/0000000173377122
700    1_
$a Soilu-Hänninen, Merja $u Division of Clinical Neurosciences, University Hospital and University of Turku, Turku, Finland $1 https://orcid.org/0000000169300229
700    1_
$a van der Walt, Anneke $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia $1 https://orcid.org/0000000242787003
700    1_
$a Butzkueven, Helmut $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia
700    1_
$a Iaffaldano, Pietro $u Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro", Bari, Italy $1 https://orcid.org/0000000323081731
700    1_
$a Trojano, Maria $u Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
700    1_
$a Glaser, Anna $u Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Hillert, Jan $u Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000273866732
710    2_
$a SPMS Research Collaboration Network
773    0_
$w MED00194908 $t Multiple sclerosis journal - experimental, translational and clinical $x 2055-2173 $g Roč. 9, č. 1 (2023), s. 20552173231153557
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36816812 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230413 $b ABA008
991    __
$a 20230421100043 $b ABA008
999    __
$a ok $b bmc $g 1922705 $s 1189112
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 9 $c 1 $d 20552173231153557 $e 20230216 $i 2055-2173 $m Multiple sclerosis journal - experimental, translational and clinical $n Mult Scler J Exp Transl Clin $x MED00194908
LZP    __
$a Pubmed-20230413

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace